SHOC2 and glioblastoma: From a translational perspective, while no clinical compounds blocking SHOC2 exist to date, the recent structural elucidation of the SHOC2 heterotrimeric complex has facilitated potential pharmacologic strategies that may be useful in glioblastoma (42–44).